ArticleBMC cancer2022

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.

Ya Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.